COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

PCN120

  • Rutkowski, J
  • Gwiosda, B
  • Lisiecka, B
  • Wladysiuk, M
  • Lis, J
  • Plisko, R
  • Rys, P

  • 1HTA Consulting, Krakow, Poland, 2Sanofi-Aventis, Warsaw, Poland

Value in Health 12(7):p A280, October 2009.
Copyright © 2009 Blackwell Publishing Ltd.